CD274 and neoplasm: At present, the biological biomarkers for the evaluation and prognosis of cancer patients benefiting from immune checkpoint blockade mainly include tumor mutation burden (TMB), mismatch repair deficiency (MMR-D), microsatellite instability (MSI), immune cell infiltration and PDL1 expression, but it is still difficult to obtain satisfactory results [2, 7].